Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.

Journal of medical genetics - 1 Aug 2010

Evans D Gareth, Ahmed Munaza, Bayliss Stuart, Howard Emma, Lalloo Fiona, Wallace Andrew

Abstract excerpt

BACKGROUND: Previous publications and utilisation of risk models for BRCA1 and BRCA2 mutation identification suggests that multiple primary disease in an individual is a strong predictor of a BRCA1/2 mutation and that this is more predictive than the same cancers occurring in close relatives. METHODS: This study assessed the pathological mutation detection rates for BRCA1, BRCA2 and the CHEK2c.1100 delC mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Family

Share to Neoplasms, Multiple Primary

Share to Ovarian Neoplasms

Share to Protein Serine-Threonine Kinases

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 20472656
DOI: 10.1136/jmg.2009.075770

Genes

BRCA1
BRCA2
CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries.PMID 20472656Read ↗

Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.Semantic proximity Read ↗

Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary CancersSemantic proximity Read ↗

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.Semantic proximity Read ↗

Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.Semantic proximity Read ↗

Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.Semantic proximity Read ↗

Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.Semantic proximity Read ↗

Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.Semantic proximity Read ↗

Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.Semantic proximity Read ↗

Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers.Semantic proximity Read ↗

Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.Semantic proximity Read ↗

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.Semantic proximity Read ↗

Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.